Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Renovaro (NASDAQ:RENB) has secured multiple U.S. patent allowances strengthening its position in the $20B biomedical AI sector. The patents focus on federated learning technology and unbiased drug discovery predictions, including U.S. Application No. 18/058,732 and recently awarded Application No. 18/058,752.
The company's breakthrough technology enables AI model training across decentralized healthcare datasets without exchanging sensitive raw data, providing bidirectional security for both data sources and AI models. The patents cover methods for integrating heterogeneous healthcare data, including EHRs, imaging, genomics, and trial data, supporting applications in drug discovery, clinical trials, rare disease research, and precision medicine.
Renovaro (NASDAQ:RENB) ha ottenuto diverse concessioni di brevetti negli Stati Uniti, rafforzando la sua posizione nel settore dell'intelligenza artificiale biomedica da 20 miliardi di dollari. I brevetti riguardano la tecnologia di apprendimento federato e previsioni imparziali nella scoperta di farmaci, inclusi il brevetto statunitense n. 18/058,732 e il pi霉 recente n. 18/058,752.
La tecnologia innovativa dell'azienda permette il training di modelli AI su dataset sanitari decentralizzati senza scambiare dati grezzi sensibili, garantendo una sicurezza bidirezionale sia per le fonti dati che per i modelli AI. I brevetti coprono metodi per integrare dati sanitari eterogenei, come cartelle cliniche elettroniche, immagini, genomica e dati di sperimentazioni, supportando applicazioni in scoperta di farmaci, sperimentazioni cliniche, ricerca sulle malattie rare e medicina di precisione.
Renovaro (NASDAQ:RENB) ha asegurado m煤ltiples concesiones de patentes en EE. UU., fortaleciendo su posici贸n en el sector de IA biom茅dica de 20 mil millones de d贸lares. Las patentes se centran en la tecnolog铆a de aprendizaje federado y predicciones imparciales para el descubrimiento de f谩rmacos, incluyendo la solicitud estadounidense No. 18/058,732 y la recientemente concedida No. 18/058,752.
La tecnolog铆a innovadora de la compa帽铆a permite entrenar modelos de IA en conjuntos de datos sanitarios descentralizados sin intercambiar datos sensibles en bruto, proporcionando seguridad bidireccional tanto para las fuentes de datos como para los modelos de IA. Las patentes cubren m茅todos para integrar datos sanitarios heterog茅neos, incluyendo registros electr贸nicos de salud, im谩genes, gen贸mica y datos de ensayos, apoyando aplicaciones en descubrimiento de f谩rmacos, ensayos cl铆nicos, investigaci贸n de enfermedades raras y medicina de precisi贸n.
Renovaro (NASDAQ:RENB)電� 氙戈淡 雮� 雼れ垬鞚� 韸鬼棃 項堦皜毳� 頇曤炒頃橃棳 200鞏� 雼煬 攴滊鞚� 靸濎潣頃� AI 攵勳暭鞐愳劀 鞛呾毳� 臧曧檾頄堨姷雼堧嫟. 鞚� 韸鬼棃霌れ潃 鞐绊暕 頃欖姷 旮办垹瓿� 韼疙枼 鞐嗠姅 鞁犾暯 氚滉铂 鞓堨浮鞐� 欷戩爯鞚� 霊愱碃 鞛堨溂氅�, 氙戈淡 於滌洂 氩堩樃 18/058,732鞕� 斓滉芳 鞀轨澑霅� 於滌洂 氩堩樃 18/058,752臧� 韽暔霅╇媹雼�.
須岇偓鞚� 順侅嫚鞝侅澑 旮办垹鞚� 氙缄皭頃� 鞗愳嫓 雿办澊韯半ゼ 甑愴櫂頃橃 鞎婈碃霃� 攵勳偘霅� 鞚橂 雿办澊韯办厠 鞝勲皹鞐� 瓯胳箿 AI 氇嵏 頃欖姷鞚� 臧�電ロ晿瓴� 頃橃棳 雿办澊韯� 靻岇姢鞕� AI 氇嵏 氇憪鞐� 雽�頃� 鞏戨癌頄� 氤挫晥鞚� 鞝滉车頃╇媹雼�. 鞚� 韸鬼棃霌れ潃 鞝勳瀽鞚橂旮半(EHR), 鞓侅儊, 鞙犾爠觳错暀, 鞛勳儊鞁滍棙 雿办澊韯� 霌� 鞚挫鞝侅澑 鞚橂 雿办澊韯半ゼ 韱淀暕頃橂姅 氚╇矔鞚� 雼る（氅�, 鞁犾暯 臧滊皽, 鞛勳儊 鞁滍棙, 頋穩 歆堩櫂 鞐瓣惮 氚� 鞝曤皜 鞚橅暀 攵勳暭鞚� 鞚戩毄鞚� 歆�鞗愴暕雼堧嫟.
Renovaro (NASDAQ:RENB) a obtenu plusieurs brevets aux 脡tats-Unis, renfor莽ant ainsi sa position dans le secteur de l'IA biom茅dicale de 20 milliards de dollars. Les brevets portent sur la technologie d'apprentissage f茅d茅r茅 et des pr茅dictions impartiales pour la d茅couverte de m茅dicaments, incluant la demande am茅ricaine n掳 18/058,732 et la r茅cente demande n掳 18/058,752.
La technologie r茅volutionnaire de l'entreprise permet l'entra卯nement de mod猫les d'IA sur des ensembles de donn茅es de sant茅 d茅centralis茅es sans 茅changer de donn茅es brutes sensibles, offrant une s茅curit茅 bidirectionnelle tant pour les sources de donn茅es que pour les mod猫les d'IA. Les brevets couvrent des m茅thodes d'int茅gration de donn茅es de sant茅 h茅t茅rog猫nes, telles que les dossiers m茅dicaux 茅lectroniques, l'imagerie, la g茅nomique et les donn茅es d'essais cliniques, soutenant des applications dans la d茅couverte de m茅dicaments, les essais cliniques, la recherche sur les maladies rares et la m茅decine de pr茅cision.
Renovaro (NASDAQ:RENB) hat mehrere US-Patenterteilungen erhalten und st盲rkt damit seine Position im 20-Milliarden-Dollar-Bereich der biomedizinischen KI. Die Patente konzentrieren sich auf f枚deriertes Lernen und unvoreingenommene Vorhersagen bei der Arzneimittelentdeckung, darunter die US-Anmeldung Nr. 18/058.732 und die k眉rzlich erteilte Anmeldung Nr. 18/058.752.
Die bahnbrechende Technologie des Unternehmens erm枚glicht das Training von KI-Modellen 眉ber dezentralisierte Gesundheitsdatens盲tze, ohne sensible Rohdaten auszutauschen, und bietet eine bidirektionale Sicherheit f眉r sowohl Datenquellen als auch KI-Modelle. Die Patente umfassen Methoden zur Integration heterogener Gesundheitsdaten, einschlie脽lich elektronischer Gesundheitsakten, Bildgebung, Genomik und Studiendaten, und unterst眉tzen Anwendungen in der Arzneimittelentdeckung, klinischen Studien, Forschung zu seltenen Krankheiten und Pr盲zisionsmedizin.
- None.
- Operating in a highly competitive and rapidly evolving AI technology sector
- Success depends on future partnerships and commercial adoption
Insights
Renovaro's new patents create a defensible moat in federated healthcare AI, strengthening its position in the lucrative biomedical AI market.
Renovaro has secured strategic patents that significantly enhance its competitive positioning in the $20 billion biomedical AI sector. The newly allowed patents address critical challenges in healthcare AI, particularly around federated learning - a technique that allows AI models to be trained across distributed datasets without centralizing sensitive patient information.
The core technical innovation in these patents revolves around two key capabilities: (1) unbiased drug discovery predictions and (2) bidirectional security in federated learning environments. These technologies solve fundamental bottlenecks in healthcare AI adoption - specifically the need to maintain privacy while still extracting value from disparate data sources like EHRs, genomics, and imaging.
What makes these patents particularly valuable is their broad applicability across high-value healthcare applications. The protected technology enables harmonization of heterogeneous healthcare data sources - a persistent challenge that has limited AI deployment in clinical settings. By establishing IP protection around methods for standardizing diverse datasets while maintaining data privacy, Renovaro has created a defensible moat in a high-growth market.
The continuation filings mentioned suggest Renovaro is building a layered patent strategy - a sophisticated approach used by technology leaders to extend protection periods and cover emerging applications of their core technology. This approach typically signals confidence in the foundational technology and creates sustained barriers to competition.
With these patents, Renovaro positions itself as an infrastructure provider rather than just a point-solution company - enabling partnerships across pharmaceutical research, clinical trials, and precision medicine applications. This platform approach, backed by defensible IP, creates multiple potential revenue streams and partnership opportunities in a market projected to reach
Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth
LOS ANGELES, CALIFORNIA / / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents, including U.S. Application No. 18/058,732 for unbiased drug discovery predictions, expand Renovaro's growing IP portfolio anchored by foundational patents U.S. No. 11,379,757 and recently awarded Application No. 18/058,752.
Key Value Drivers:
Protected Competitive Moat in federated learning for healthcare, with continuation filings extending IP coverage by establishing broad protection around harmonizing biomedical data and applying frameworks for AI-powered prediction of both beneficial and harmful treatment effects.
Enhances Partnership Opportunities by supporting high-value applications such as high-fidelity integration of heterogeneous datasets - including electronic health records (EHRs), imaging, genomics, and trial data - across distributed environments, directly enabling applications in drug discovery, clinical trials, rare disease research, and precision medicine.
Breakthrough in Federated and Secure AI Learning: The newly issued patent covers a novel federated learning architecture that enables advanced AI model training across decentralized healthcare datasets - such as those held by hospitals, research institutions, or biopharma partners - without requiring the exchange of sensitive raw data. This innovation provides robust bidirectional security, protecting both the underlying data sources and the integrity of the resulting AI models, and positions the company at the forefront of privacy-preserving AI in healthcare
Scalable and Reproducible AI Models designed for real-world deployment across heterogeneous data environments - an essential capability for future pharmaceutical and clinical partners.
Robust IP Pipeline: Multiple continuation filings underway, providing sustained innovation and patent coverage over time.
Renovaro's newly allowed patents include innovations titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions" and "Methods, Systems, and Frameworks for Federated Learning While Ensuring Bi-Directional Data Security". These methods address critical pain points in biomedical AI, such as data sparsity, source heterogeneity, and lack of model transferability - paving the way for reproducible AI models in precision medicine. These filings also deepen the company's IP foundation by addressing key bottlenecks in the biomedical AI space - specifically, the integration of heterogeneous data such as EHRs, genomics, imaging, and clinical trial results into standardized pipelines capable of producing clinically relevant, reproducible insights.
These capabilities are particularly critical for applications in rare disease research, trial optimization, and therapeutic targeting - areas with strong unmet needs and have high-value partnership potential.
"Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro.
With additional patents pending and a portfolio designed to scale with evolving interoperability standards and regulatory demands, Renovaro continues to solidify its position as a platform company with durable, defensible technology in a market estimated to reach over
About Renovaro (NASDAQ: RENB)
Renovaro is a forward-looking biotechnology company harnessing the power of artificial intelligence and data science to develop innovative therapies and diagnostics in oncology, infectious disease, and autoimmune disorders. By integrating cutting-edge machine learning with biomedical research, Renovaro aims to dramatically improve treatment outcomes and enable earlier disease detection.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our filings with the SEC for a discussion of these risks.
Contact:
SOURCE: Renovaro Biosciences
View the original on ACCESS Newswire
FAQ
What patents did Renovaro (RENB) receive in July 2025?
How does Renovaro's federated learning technology work in healthcare?
What is the market size for Renovaro's biomedical AI technology?
What applications does Renovaro's patent portfolio support?
How do these patents strengthen Renovaro's competitive position?
